Bromberg M B, Wald J J, Forshew D A, Feldman E L, Albers J W
Department of Neurology, University of Utah, Salt Lake City, USA.
J Neurol Sci. 1997 Sep 1;150(1):59-62. doi: 10.1016/s0022-510x(97)05370-7.
Ten patients with myasthenia gravis were randomized to azathioprine or prednisone as the initial immunomodulating drug and followed for over one year. Of five patients randomized to azathioprine, two had idiosyncratic reactions and were immediately crossed over to prednisone. Two patients completed one year on azathioprine with little or no change in level of function and were crossed over to prednisone and showed greater improvement. The fifth patient on azathioprine had a satisfactory improvement and continued on it during the second year. All patients initially randomized to prednisone improved, but the degree varied among patients. The side effects of azathioprine were idiosyncratic reactions. The side effects of prednisone were manageable.
10名重症肌无力患者被随机分为两组,分别初始使用硫唑嘌呤或泼尼松作为免疫调节药物,并随访一年以上。在随机分配使用硫唑嘌呤的5名患者中,2名出现特异反应,随即转而使用泼尼松。2名使用硫唑嘌呤满一年的患者功能水平几乎没有变化,转而使用泼尼松后有了更大改善。第5名使用硫唑嘌呤的患者有令人满意的改善,并在第二年继续使用该药。所有初始随机分配使用泼尼松的患者均有改善,但改善程度因人而异。硫唑嘌呤的副作用为特异反应。泼尼松的副作用易于控制。